📰 Acb News
Page 23 - Acb News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Acb. Real-time updates on events, politics, business and more.
March 28, 2023
The European Union patent body will oversee a new process to set fair royalties on patents for technologies widely used in products like cellphones, according to a draft EU regulation that seeks to reduce litigation over royalty disputes.
March 27, 2023
Britain's antitrust regulator said on Monday it was looking into whether the anticipated acquisition by Électricité de France SA of the nuclear steam power business owned by General Electric Co could lead to competition concerns.
March 26, 2023
Aurora Cannabis Inc. (NYSE:ACB – Get Rating) has earned an average recommendation of “Hold” from the seven research firms that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price objective among analysts […]
March 25, 2023
Shares of Aurora Cannabis Inc. (TSE:ACB – Get Rating) have been assigned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating. The average twelve-month price target among brokers that have updated their coverage on the stock […]
March 24, 2023
On a complaint the ACB booked a case and trapped the DEO Nampally Rajesh and senior assistant N Rama Krishna Goud.
March 17, 2023
The ACB claimed that from March 2007 till March 2014, the accused persons amassed 45.32% higher income than his known sources.
March 16, 2023
The state anti-corruption bureau (ACB) has served a notice to Uddhav Thackeray faction MLA Rajan Salvi's family in a disproportionate assets case.
March 16, 2023
The official had allegedly demanded Rs 7 lakh for sending a proposal for approval of the eligibility to get the compensation package under the NMIA project.
March 13, 2023
Pacific Biosciences of California Inc. (NASDAQ:PACB) price closed lower on Friday, March 10, dropping -5.36% below its previous close. A look at the daily price movement shows that the last close reads $8.77, with intraday deals fluctuated between $8.01 and $8.72. The company’s 5Y monthly beta was
March 13, 2023
In the latest trading session, 1.29 million Pacific Biosciences of California Inc. (NASDAQ:PACB) shares changed hands as the company’s beta touched 1.64. With the company’s most recent per share price at $8.72 changing hands around $0.42 or 5.06% at last look, the market valuation stands at $2.1